Screener
Arcus Biosciences RCUS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts payable ($12 and $24 to a related party) | $34 | $42 |
| Deferred revenue ($11 and $35 to a related party) | 19 | 35 |
| Other current liabilities | 145 | 154 |
| Total current liabilities | 198 | 231 |
| Deferred revenue, noncurrent ($19 and $43 to a related party) | 37 | 43 |
| Long-term debt | 101 | 99 |
| Other noncurrent liabilities | 124 | 135 |
| Commitments |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's total current liabilities?
- Arcus Biosciences (RCUS) reported total current liabilities of $198M in Q2 2026.
- How has Arcus Biosciences's total current liabilities changed year-over-year?
- Arcus Biosciences's total current liabilities decreased by 5.7% year-over-year, from $210M to $198M.
- What is the long-term trend for Arcus Biosciences's total current liabilities?
- Over 5 years (2020 to 2025), Arcus Biosciences's total current liabilities has grown at a 13.7% compound annual growth rate (CAGR), from $121.67M to $231M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Arcus Biosciences's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude